Results 81 to 90 of about 3,194,674 (312)
Adverse event reported in the Flury’s study.
, 2019 Adverse event reported in the Flury’s study.
Meng Xu (62933) +5 more
core +1 more source
Degradation mechanism of the von Willebrand factor A2 domain by nattokinase
FEBS Letters, EarlyView.Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto +3 more
wiley +1 more source
, 2020 Tomohito Wakabayashi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Sayaka Ueno, Hiroko Kambara, Tatsuya Iida, Takahiro Nakatsuji, Mayako Uchida, Kazunori Iwanaga Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences,
Kambara H +9 more
core
Adverse event profiles for all investigated agents.
, 2016 Adverse event profiles for all investigated agents.
Alessa von Wolff (834209) +6 more
core +1 more source
Code lists to define serious adverse event outcomes.
, 2023 Code lists to define serious adverse event outcomes.
Andrew Clegg (7713461) +11 more
core +1 more source
Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy
FEBS Letters, EarlyView.The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley +1 more source
Frontiers in PharmacologyBackgroundLumateperone has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in adults since 2019, however, there is still a lack of data report on adverse reactions in real-world settings.
Yanjing Zhang +12 more
doaj +1 more source
Adverse event profiles during treatment.
, 2014 AST aspartate aminotransferase; ALT alanine transaminase.Adverse event profiles during treatment.
Meng Su (136681) +5 more
core +1 more source
Studies providing indirect adverse event definition only (n = 4).
, 2022 Studies providing indirect adverse event definition only (n = 4).
Lindsay M. Gorrell (13104751) +4 more
core +1 more source
Molecular Oncology, EarlyView.In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source